| Name | Title | Contact Details |
|---|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA).
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.